|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"tai d"
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2024-12-19 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.]
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國立成功大學 |
2023 |
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial
|
Tempero, M.A.;Pelzer, U.;O'Reilly, E.M.;Winter, J.;Oh, D.-Y.;Li, C.-P.;Tortora, G.;Chang, H.-M.;Lopez, C.D.;Bekaii-Saab, T.;Ko, A.H.;Santoro, A.;Park, J.O.;Noel, M.S.;Frassineti, G.L.;Shan, Y.-S.;Dean, A.;Riess, H.;Van, Cutsem E.;Berlin, J.;Philip, Philip P.;Moore, Moore M.;Goldstein, D.;Tabernero, J.;Li, M.;Ferrara, S.;Le, Bruchec Y.;Zhang, G.;Lu, B.;Biankin, A.V.;Reni, M.;Epstein, R.;Vasey, P.;Shapiro, J.;Burge, M.;Chua, Y.J.;Harris, M.;Pavlakis, N.;Tebbutt, N.;Prager, G.;Dittrich, C.;L�ngle, F.;Philipp-Abbrederis, K.;Greil, R.;St�ger, H.;Girschikofsky, M.;Kuehr, T.;Van, Laethem J.-L.;Laurent, S.;Dhani, N.;Ko, Y.J.;Dowden, S.;Kavan, P.;Tehfe, M.�.;Kubala, E.;Kohoutek, M.;Pfeiffer, Pfeiffer P.;Yilmaz, M.;Parner, V.;Salminen, T.;Soveri, L.-M.;Korkeila, E.;Osterlund, P.;Taieb, J.;Tougeron, D.;Artru, P.;Caroli-Bosc, F.X.;Guimbaud, R.;Turpin, A.;Walter, T.;Bachet, J.B.;Kunzmann, V.;Kreth, F.;Block, A.;Venerito, M.;Oettle, H.;Karthaus, M.;Trojan, J.;Folprecht, G.;Lerch, M.;Kullmann, F.;Reiser, M.;Heinemann, V.;W�rns, M.-A.;Schulz, H.;Garlipp, B.;Yau, T.;Chan, L.S.;Juhasz, B.;Landherr, Landherr L.;Pinter, T.;Bodoky, G.;Kah�n, Z.;McDermott, R.;Power, D.;Gianni, L.;Siena, Siena S.;Milella, Milella M.;Falcone, A.;Berardi, R.;Bagal�, C.;Di, Costanzo F.;Roila, F.;Ardizzoni, Ardizzoni A.;Maiello, E.;Fanello, S.;Wilmink, J.;Willem, De Groot J.;Creemers, G.;Barroso, E.;Rodrigues, T.;Sarmento, C.;Chee, Chee C.E.;Tai, D.;Mercade, T.M.;Medina, Medina M.H.;Mena, A.C.;Santasusana, J.M.;Flor, Oncala M.J.;Martin, C.G.;Lopez, R.;Mu�oz, A.;Garcia, R.V.;Ales, I.;S�ez, B.L.;Rivera, F.;Sastre, J.;Wu, C.-C.;Tien, Y.-W.;Chan, D.-C.;Hwang, T.-L.;Evans, J.;Wadsley, J.;Corrie, P.;Biankin, A.;Ko, A.;Cardin, D.;Chiorean, E.;Bendell, J.;Noonan, A.;Kindler, H.;Fernando, N.;Beg, M.;George, T.;Noel, M.;Loconte, N.;Arena, F.;Posey, J.;Malhotra, R.;Lopez, C.;Sohal, D.;McWilliams, R.;Brenner, W.;Womack, M.;Seth, R.;Lyer, R.;Bahary, N.;Marsh, R.;Ramirez, Ramirez R.;Chua, Chua C.;Reeves, J.;Manji, G.;El-Khoueiry, A.;Weaver, R.;Sahai, V.;Messersmith, W.;Dreicer, R.;Zakari, A.;Bullock, A.;Musher, B.;Borad, M.;Kim, E.;Bajor, D.;Huyck, T.;Hatoum, Hatoum H.;Xiong, H.;Pasche, B.;Lacy, J.;Olowokure, Olowokure O.;Cohn, A.;Richards, D.;Martin, R.;Paulson, A.;Fanta, P.;Krishnamurthi, S.;Oberstein, P.;Fuloria, J. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; Chia-Chi Lin; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A. |
| 國家衛生研究院 |
2022-09 |
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan
|
Yau, T;Tai, D;Chan, SL;Huang, YH;Choo, SP;Hsu, C;Cheung, TT;Lin, SM;Yong, WP;Lee, J;Leung, T;Shum, T;Yeung, CSY;Tai, AY;Law, ALY;Cheng, AL;Chen, LT |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 國家衛生研究院 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, LT;Martinelli, E;Cheng, AL;Pentheroudakis, G;Qin, S;Bhattacharyya, GS;Ikeda, M;Lim, HY;Ho, GF;Choo, SP;Ren, Z;Malhotra, H;Ueno, M;Ryoo, BY;Kiang, TC;Tai, D;Vogel, A;Cervantes, A;Lu, SN;Yen, CJ;Huang, YH;Chen, SC;Hsu, C;Shen, YC;Tabernero, J;Yen, Y;Hsu, CH;Yoshino, T;Douillard, JY |
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
